April 13, 2017 08:37 AM EDT
Pharma

Ed­i­tas’ ri­vals ap­peal a re­cent set­back on patent fight, map­ping a glob­al war for CRISPR su­prema­cy

John Carroll

Editor & Founder

The gene edit­ing con­sor­tium that has sought to bot­tle up ri­val Ed­i­tas $ED­IT with claims of patent in­fringe­ment are mak­ing a fed­er­al case out of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times